抗青光眼药物的流入与流出。
The inflow and outflow of anti-glaucoma drugs.
作者信息
Woodward David F, Gil Daniel W
机构信息
Department of Biological Sciences, Allergan, Irvine, CA 92612, USA.
出版信息
Trends Pharmacol Sci. 2004 May;25(5):238-41. doi: 10.1016/j.tips.2004.03.002.
The treatment of glaucoma by reducing intraocular pressure has relied traditionally on inhibiting aqueous humor secretion (inflow). However, recent therapeutic approaches have targeted aqueous humor outflow. Prostanoid FP receptor agonists selectively increase uveoscleral outflow and the prostamide analog bimatoprost alters trabecular and uveoscleral outflow. An emerging therapeutic strategy is direct neuroprotection of retinal ganglion cells, which are selectively lost in glaucoma.
传统上，通过降低眼压来治疗青光眼主要依靠抑制房水分泌（流入）。然而，最近的治疗方法已将目标指向房水流出。前列腺素FP受体激动剂可选择性增加葡萄膜巩膜流出，而前列腺酰胺类似物比马前列素可改变小梁和葡萄膜巩膜流出。一种新兴的治疗策略是对视网膜神经节细胞进行直接神经保护，这些细胞在青光眼中会选择性丧失。
Zotero 插件